Halsey Associates Inc. CT Lowers Position in Icon Plc (ICLR)
Halsey Associates Inc. CT trimmed its position in shares of Icon Plc (NASDAQ:ICLR) by 18.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,915 shares of the medical research company’s stock after selling 1,985 shares during the period. Halsey Associates Inc. CT’s holdings in Icon Plc were worth $1,015,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Shine Investment Advisory Services Inc. bought a new position in Icon Plc during the second quarter valued at about $103,000. Acrospire Investment Management LLC increased its stake in Icon Plc by 20.1% during the second quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock valued at $117,000 after acquiring an additional 200 shares during the period. Parallel Advisors LLC increased its stake in Icon Plc by 20.7% during the second quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock valued at $133,000 after acquiring an additional 217 shares during the period. SG Americas Securities LLC bought a new position in Icon Plc during the third quarter valued at about $148,000. Finally, Huntington National Bank increased its stake in Icon Plc by 5.0% during the second quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock valued at $159,000 after acquiring an additional 77 shares during the period. Hedge funds and other institutional investors own 89.75% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Halsey Associates Inc. CT Lowers Position in Icon Plc (ICLR)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/11/20/halsey-associates-inc-ct-lowers-position-in-icon-plc-iclr.html.
Several equities analysts recently issued reports on ICLR shares. Mizuho boosted their price target on Icon Plc from $104.00 to $108.00 and gave the company a “neutral” rating in a research note on Thursday, July 27th. Credit Suisse Group reaffirmed a “buy” rating on shares of Icon Plc in a report on Friday, July 28th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Icon Plc in a report on Sunday, July 30th. SunTrust Banks, Inc. raised Icon Plc from a “hold” rating to a “buy” rating and lifted their price objective for the company from $93.00 to $126.00 in a report on Monday, July 31st. Finally, KeyCorp reaffirmed an “overweight” rating on shares of Icon Plc in a report on Monday, July 31st. Four analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $121.00.
Shares of Icon Plc (ICLR) traded up $1.57 on Monday, hitting $117.25. The stock had a trading volume of 271,200 shares, compared to its average volume of 366,445. The firm has a market cap of $6,349.32, a P/E ratio of 22.50, a P/E/G ratio of 1.81 and a beta of 0.56. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 0.31. Icon Plc has a fifty-two week low of $73.76 and a fifty-two week high of $124.48.
Icon Plc (NASDAQ:ICLR) last announced its earnings results on Thursday, October 26th. The medical research company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.32 by $0.03. The business had revenue of $440.30 million for the quarter, compared to the consensus estimate of $438.09 million. Icon Plc had a return on equity of 28.42% and a net margin of 16.37%. Icon Plc’s revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.19 EPS. sell-side analysts anticipate that Icon Plc will post 5.36 EPS for the current fiscal year.
Icon Plc Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Stock Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related stocks with our FREE daily email newsletter.